All In Biotech

Drug Trial Radar · NCT01077154

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Recurrence (D-CARE)

Last checked: Nov 20, 2026Latest source record: Sep 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,509 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

4,509

Actual

Start

Jun 2, 2010

Primary completion

Aug 31, 2017

Study completion Mar 26, 2018

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Feb 26, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.

Conditions

  • Breast Cancer

Interventions

  • PlaceboDrug

    Administered subcutaneously for up to 5 years

  • DenosumabDrug

    Administered subcutaneously for up to 5 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bone Metastasis-free Survival (BMFS)Time frame: From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.

Locations

459 sites in 39 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Tucson, Arizona

  • Research Site

    Jonesboro, Arkansas

  • Research Site

    Alhambra, California

  • Research Site

    Anaheim, California

  • Research Site

    Beverly Hills, California

  • Research Site

    Campbell, California

  • Research Site

    Fresno, California

  • Research Site

    Fullerton, California

  • Research Site

    La Verne, California

  • Research Site

    Lancaster, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Los Angeles, California

  • Research Site

    Northridge, California

  • Research Site

    Redondo Beach, California

  • Research Site

    Santa Barbara, California

  • Research Site

    Santa Maria, California

  • Research Site

    Torrance, California

  • Research Site

    Denver, Colorado

  • Research Site

    Grand Junction, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Boynton Beach, Florida

  • Research Site

    Coral Springs, Florida

  • Research Site

    Fort Lauderdale, Florida

  • Research Site

    Hollywood, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Melbourne, Florida

  • Research Site

    Athens, Georgia

  • Research Site

    Niles, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Cedar Rapids, Iowa

  • Research Site

    Hutchinson, Kansas

  • Research Site

    Wichita, Kansas

  • Research Site

    Paducah, Kentucky

  • Research Site

    Annapolis, Maryland

  • Research Site

    Baltimore, Maryland

  • Research Site

    Bethesda, Maryland

  • Research Site

    Columbia, Maryland

Showing 40 of 459 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.